Good point with upstream availability issues. I never really looked those up, simply because I have zero idea how vaccine manufacturing works. Until now, I only focused on the downstream side, everything after manufacturing. And I don't like what I see on that end, especially in Germany.

It is almost like the world at are is getting a crash course in supply chain management. One could have asked experts on that before, sure, but why bother when local politians need credits for their election campaigns, right?